# ALMS catalysts: ALUMIS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alms/catalysts

> ALUMIS INC. (ALMS) has 5 upcoming catalysts. The next is the envudeucitinib trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ALMS?

ALUMIS INC. (ALMS) has 5 upcoming catalysts. The next is the envudeucitinib trial start, 1H 2027. Press release filed with the SEC (EX-99): "Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system penetrant TYK2 inhibitor, in patients with Parkinson's disease, in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/alms/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001847367-26-000016, https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/companies/alms/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ALUMIS INC. |
| Ticker | ALMS (Nasdaq) |
| SEC CIK | 1847367 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/alms |

## Cash runway

Cash $57.7M as of 2026-09-30; quarterly burn $79.6M; about 2.2 months of runway at that rate (XBRL company facts, accession 0001847367-26-000024).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2024 | [Envudeucitinib trial start](https://sec-api.dev/pdufa/envudeucitinib) | ALMS |  | completed | "In addition to our Phase 3 program in PsO, which we announced in July 2024 had commenced patient dosing, we have initiated a Phase 2b trial of ESK-001 in SLE." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000028/alms-20250331x10q.htm)) |
| November 13, 2024 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)) |
| March 19, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)) |
| May 14, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514xex99d1.htm)) |
| 2H 2025 | [Envudeucitinib trial start](https://sec-api.dev/pdufa/envudeucitinib) | ALMS |  | scheduled | "We also plan to initiate a Phase 2 trial of A-005 in multiple sclerosis in the second half of 2025 and expect data from ESK-001's Phase 2b clinical trial in systemic lupus erythematosus in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)) |
| August 13, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)) |
| September 19, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06586112 (A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06586112)) |
| September 23, 2025 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | completed | "NCT06588738 (A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06588738)) |
| November 13, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)) |
| Q1 2026 | [Lonigutamab topline data readout](https://sec-api.dev/pdufa/lonigutamab) | ALMS |  | scheduled | "Anticipated Milestones o Envu: topline data from ONWARD1 and ONWARD2 in moderate-to-severe plaque psoriasis are expected early in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)) |
| Q1 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | scheduled | "〉 Envu Psoriasis top-line data expected early Q1 2026 and SLE Phase 2b top-line data expected Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1.htm)) |
| Q1 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | scheduled | "o Topline data from ONWARD1 and ONWARD2 are expected early in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)) |
| Q1 2026 | [Envudeucitinib topline data readout](https://sec-api.dev/pdufa/envudeucitinib) | ALMS |  | scheduled | "Our teams have been working diligently, and we are eagerly anticipating key milestones ahead - with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus (SLE) in the third quarter," said Martin Babler, President and Chief Executive Officer of Alumis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)) |
| Q1 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | scheduled | "With the favorable results in our Phase 2 clinical trial in PsO, we have initiated our Phase 3 ONWARD clinical program, which consists of two parallel Phase 3 clinical trials of envu in this indication and for which we expect to report topline results early in the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000050/alms-20250930x10q.htm)) |
| January 6, 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS | moderate-to-severe plaque psoriasis | completed, positive | "On January 6, 2026 we announced positive topline results from our Phase 3 ONWARD1 and ONWARD2 global Phase 3, multi-center, randomized, double-blind placebo-controlled clinical trials, evaluating envu in patients with PsO." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)) |
| March 19, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Year End 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)) |
| Q2 2026 | [Envudeucitinib trial start](https://sec-api.dev/pdufa/envudeucitinib) | ALMS |  | scheduled | "o Alumis will provide an update of the TYK2 franchise strategy for both programs in the second quarter of 2026, including a timing update for commencing A-005's Phase 2 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)) |
| May 14, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)) |
| June 23, 2026 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | SLE | completed | "NCT05966480 (Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05966480)) |
| Q3 2026 | [Envudeucitinib topline data readout](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | systemic lupus erythematosus, with topline data | scheduled | "- Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)) |
| Q3 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | scheduled | "〉 Ongoing global Phase 2b LUMUS trial, expected topline readout in Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925086612/tm2525079d1_ex99-1.htm)) |
| Q3 2026 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | ALMS |  | scheduled | "LUMUS Phase 2b Trial: Topline Results Expected Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926078507/tm2619143d1_ex99-1.htm)) |
| Q3 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS | moderate-to-severe plaque psoriasis | scheduled | "In addition, envu is currently being evaluated in a Phase 2 clinical trial in patients with systemic lupus erythematosus ("SLE"), for which we expect to report topline results in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm)) |
| Q3 2026 | [ALUMIS INC. topline data readout](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | scheduled | "o Envu: topline data from LUMUS in SLE are expected in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)) |
| August 13, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Second Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)) |
| Q4 2026 | [Envudeucitinib NDA/BLA submission](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | with moderate-to-severe plaque psoriasis, the timing of Alumis' topline readout | scheduled | "- Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)) |
| Q4 2026 | [Envudeucitinib topline data readout](https://sec-api.dev/pdufa/envudeucitinib) | ALMS |  | scheduled | "Babler added, "We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)) |
| November 12, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)) |
| 1H 2027 | [Envudeucitinib trial start](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Parkinson's disease | scheduled | "Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system penetrant TYK2 inhibitor, in patients with Parkinson's disease, in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)) |
| December 2027 | [Envudeucitinib primary completion](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | scheduled | "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739435)) |
| Dec 2027 to Mar 2028 | [Envudeucitinib topline data readout](https://sec-api.dev/pdufa/envudeucitinib) | ALMS | Plaque Psoriasis | scheduled | "NCT05739435 (Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-01 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739435)) |
| November 2028 | [Open-label envudeucitinib primary completion](https://sec-api.dev/pdufa/open-label-envudeucitinib) | ALMS | Plaque Psoriasis; Psoriasis (PsO); Psoriasis | scheduled | "NCT06846541 (Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846541)) |
| Nov 2028 to Feb 2029 | [Open-label envudeucitinib topline data readout](https://sec-api.dev/pdufa/open-label-envudeucitinib) | ALMS | Plaque Psoriasis; Psoriasis (PsO); Psoriasis | scheduled | "NCT06846541 (Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Alumis Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846541)) |

## Drugs

- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib): systemic lupus erythematosus, with topline data, with moderate-to-severe plaque psoriasis, the timing of alumis' topline readout, parkinson's disease, moderate-to-severe plaque psoriasis, the timing, SLE, Plaque Psoriasis
- [Lonigutamab](https://sec-api.dev/pdufa/lonigutamab): 
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib): Plaque Psoriasis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alms/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALMS catalysts: ALUMIS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alms/catalysts

```bibtex
@misc{secapidev_companies_alms_catalysts_20261116,
  title        = {ALMS catalysts: ALUMIS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alms/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alms_catalysts_20261116","title":"ALMS catalysts: ALUMIS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alms/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
